Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Celldex Therapeutics Inc

Healthcare US CLDX

29.77USD
0.87(3.01%)

Last update at 2026-06-03T20:00:00Z

Day Range

28.7029.86
LowHigh

52 Week Range

17.8535.79
LowHigh

Fundamentals

  • Previous Close 28.90
  • Market Cap2687.36M
  • Volume876113
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-283.98701M
  • Revenue TTM1.54M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM -243.52899M
  • Diluted EPS TTM-3.88

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -258.80000M -157.86300M -141.42900M -112.32500M -70.73800M
Minority interest - - - - -
Net income -258.80000M -157.86300M -141.42900M -122.78300M -70.51100M
Selling general administrative 43.80M 38.55M 30.91M 27.20M 20.49M
Selling and marketing expenses - - - - -
Gross profit 1.50M -156.53000M -111.12800M 2.36M 4.65M
Reconciled depreciation 3.38M 3.18M 2.92M 2.90M 3.07M
Ebit -258.80000M -195.07800M -142.04200M -115.23400M -71.24300M
Ebitda -255.42000M -191.90100M -139.03400M -101.86700M -67.55800M
Depreciation and amortization 3.38M 3.18M 3.01M 13.37M 3.69M
Non operating income net other - - - - 0.51M
Operating income -287.40000M -195.07800M -154.54200M -115.23400M -71.24300M
Other operating expenses 288.90M 202.10M 161.43M 109.45M 73.80M
Interest expense - - - -2.90900M 0.11M
Tax provision - - 0.00000M 0.00000M -0.22700M
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - 3.50M
Other items - - - - -
Income tax expense - -157.86300M 2.84M 10.46M -0.22700M
Total revenue 1.50M 7.02M 6.88M 2.36M 4.65M
Total operating expenses 288.90M 38.55M 43.41M 109.45M 73.80M
Cost of revenue - 163.55M 118.01M - -
Total other income expense net 28.60M 37.22M 13.11M 2.91M 0.51M
Discontinued operations - - - - -
Net income from continuing ops -258.75700M -157.86300M -124.61000M -112.32500M -70.51100M
Net income applicable to common shares - - - -112.32500M -70.51100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 582.98M 792.34M 465.63M 352.74M 444.65M
Intangible assets 27.19M 27.19M 27.19M 31.30M 30.26M
Earning assets - - - - -
Other current assets 14.08M 21.18M 5.47M 12.74M 2.59M
Total liab 55.82M 45.34M 36.46M 26.53M 25.18M
Total stockholder equity 527.16M 747.00M 429.17M 326.20M 419.48M
Deferred long term liab - - - - -
Other current liab 48.26M 34.78M 26.02M 13.82M 1.55M
Common stock 0.07M 0.07M 0.06M 0.05M 0.05M
Capital stock 0.07M 0.07M 0.06M 0.05M 0.05M
Retained earnings -1813.98100M -1555.22400M -1397.36100M -1255.93200M -1143.60700M
Other liab - - - 5.33M 7.35M
Good will - - - - -
Other assets - - - 0.10M 0.10M
Cash 28.87M 28.36M 34.81M 29.43M 39.14M
Cash and equivalents - - - - -
Total current liabilities 50.99M 39.50M 31.12M 18.61M 16.53M
Current deferred revenue - - - - 12.00M
Net debt -26.53500M -24.54300M -32.27200M -25.39600M -36.10100M
Short term debt 1.55M 1.45M 1.61M 1.45M 1.75M
Short long term debt - - - - -
Short long term debt total 2.34M 3.81M 2.54M 4.03M 3.04M
Other stockholder equity 2337.45M 2298.85M 1823.17M 1580.83M 1561.14M
Property plant equipment - - - 7.75M 6.52M
Total current assets 534.66M 747.16M 431.69M 317.69M 410.84M
Long term investments - - - - -
Net tangible assets - - - 299.01M 392.29M
Short term investments 489.70M 696.92M 386.88M 275.52M 369.11M
Net receivables 2.02M 0.70M 4.53M 0.35M 0.17M
Long term debt - - - - -
Inventory - - 0.00000M -0.34700M -0.17200M
Accounts payable 1.18M 3.27M 3.49M 3.34M 1.23M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 3.63M 3.31M 3.31M 1.26M 1.89M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -1143.60700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 13.36M 9.75M 0.11M 0.10M 0.10M
Deferred long term asset charges - - - - -
Non current assets total 48.32M 45.18M 33.93M 35.04M 33.81M
Capital lease obligations 2.34M 3.81M 2.54M 4.03M 3.04M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 211.79M -290.12900M -105.78200M 89.94M -214.93400M
Change to liabilities - - - 3.12M 3.65M
Total cashflows from investing activities 209.07M -290.12900M - 89.94M -216.15600M
Net borrowings - - - - -
Total cash from financing activities 2.39M 441.45M 218.46M 4.08M 272.37M
Change to operating activities - - - -6.84600M -6.28100M
Net income -258.75700M -157.86300M -141.42900M -112.32500M -70.51100M
Change in cash 0.52M -6.45800M 5.38M -9.71400M -4.69300M
Begin period cash flow 28.36M 34.81M 29.43M 39.14M 43.84M
End period cash flow 28.87M 28.36M 34.81M 29.43M 39.14M
Total cash from operating activities -210.94500M -157.77800M -107.29100M -103.73200M -60.90900M
Issuance of capital stock 0.00000M 432.30M 216.22M 0.00000M 269.89M
Depreciation -2.47500M 3.18M 3.01M 2.90M 3.07M
Other cashflows from investing activities -2.71400M -1.91900M - - 0.03M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -1.31500M 1.93M -2.28100M -0.17500M 1.57M
Sale purchase of stock - - - - 272.37M
Other cashflows from financing activities 2.39M 9.15M 2.24M 4.08M 2.48M
Change to netincome - - - 9.60M 7.59M
Capital expenditures 2.71M 1.92M 1.82M 1.83M 1.25M
Change receivables - - - - 1.57M
Cash flows other operating - - - - -72.38700M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -4.69300M
Change in working capital 14.06M -21.60100M 13.46M -3.89800M -1.05400M
Stock based compensation 36.22M 34.24M 23.89M 15.61M 8.95M
Other non cash items 0.01M -15.73300M -6.22200M -5.78900M -1.13800M
Free cash flow -213.65900M -159.69700M -109.10900M -105.56000M -62.15800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CLDX
Celldex Therapeutics Inc		 0.87 3.01% 29.77 - - 1739.39 5.10 1405.26 -17.3415
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.38 0.89% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Celldex Therapeutics Inc

Perryville III Building, Hampton, NJ, United States, 08827

Key Executives

Name Title Year Born
Mr. Anthony S. Marucci M.B.A. Founder, Pres, CEO & Director 1962
Dr. Tibor Keler Founder, Chief Scientific Officer & Exec. VP 1959
Mr. Sam Martin Sr. VP, CFO, Sec. & Treasurer 1971
Mr. Freddy A. Jimenez Esq. Sr. VP & Gen. Counsel 1969
Dr. Diane C. Young M.D. Sr. VP & Chief Medical Officer 1957
Prof. Joseph P. Schlessinger Ph.D. Co-Founder & Member of Scientific Advisory Board 1945
Ms. Sarah Cavanaugh Sr. VP of Corp. Affairs & Admin. 1975
Patrick Till Sr. Director of Investor Relations & Corp. Communications NA
Dr. Ronald A. Pepin Chief Bus. Officer & Sr. VP 1956
Ms. Elizabeth Crowley Chief Product Devel. Officer & Sr. VP 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.